Randomized, open-label, phase Ⅱ trial of everolimus versus thalidomide in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma
| Autor: | Xiaojie Fang, Fangfang Li, Qing Liu, He Huang, Tongyu Lin, Limei Zhang, Xueying Li, Suxia Lin, Fushen Sha, Zhao Wang, Quanguang Ren, Huang Ming Hong, Chen Peng |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Everolimus business.industry medicine.disease Lymphoma Thalidomide 03 medical and health sciences 0302 clinical medicine First line therapy International Prognostic Index immune system diseases hemic and lymphatic diseases 030220 oncology & carcinogenesis Internal medicine medicine In patient Open label business Diffuse large B-cell lymphoma 030215 immunology medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 36:7560-7560 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2018.36.15_suppl.7560 |
| Popis: | 7560Background: Patients with diffuse large B-cell lymphoma (DLBCL) with a high International Prognostic Index (IPI) are at higher risk for relapse after a complete response (CR) to first-line ritu... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|